Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Summary The Top 10 R&D Spending Indian Biopharma Companies of 2026 reflect the country’s growing commitment to pharmaceutical innovation, advanced drug develop...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
Latest Developments in the Biosimilar Market The global pharmaceutical industry is witnessing rapid growth in the biosimilars market as patents for several blockbuster biologic drugs begin to ex...
Key Highlights: Implications: The expanded BAT2506 deal gives Intas a late‑stage TNF‑α biosimilar in a broad immunology class, reinforcing its biologics presence in rheumatology ...
